MacroGenics, Inc. (MGNX)

Over the past six months, MacroGenics' stock price has experienced significant volatility and gains. Key events include the FDA lifting a clinical hold on the Phase 2 LINNET study, an expanded ZYNYZ royalty deal, analyst upgrades and price target increases, clinical data presentations, and a leadership change with Eric Risser becoming CEO.

There is no explicit indication of significant demand seasonality for MacroGenics, Inc.'s products and services. Demand is primarily driven by disease prevalence, treatment efficacy, regulatory approvals, and market access, rather than seasonal patterns.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company in Rockville, Maryland, focused on developing monoclonal antibody-based therapeutics for cancer. The company uses technology platforms like DART, TRIDENT, and ADC. Key programs include lorigerlimab, a bispecific PD-1 × CTLA-4 DART molecule; MGC026, an ADC targeting B7-H3; MGC028, an ADC targeting ADAM9; and MGD024, a bispecific CD123×CD3 DART molecule. MacroGenics has a commercial-scale cGMP manufacturing facility and collaborations with companies like Incyte Corporation and Gilead Sciences, accumulating over $1.6 billion in non-dilutive funding.

MacroGenics, Inc. is headquartered in Rockville, Maryland, United States. While primarily focused on the U.S. market, its collaborations with global companies suggest a broader reach for product development and potential commercialization.

MacroGenics' brand reputation has been influenced by clinical trial holds, analyst downgrades, positive clinical data, and collaborations. The partial clinical hold on the LINNET study and analyst downgrades negatively impacted reputation, while positive clinical data and expanded collaborations contributed positively. The appointment of Eric Risser as CEO could enhance focus and capital efficiency.

MacroGenics' ownership is mainly institutional, with over 50% of shares held by institutional investors. Major institutional owners include Armistice Capital, Llc, Vanguard Group Inc, and Renaissance Technologies Llc. Insider ownership is around 3-4%, and the general public holds about a 21% stake.